At the time of writing, Bioventus Inc [BVS] stock is trading at $7.29, up 18.73%. An important factor to consider is whether the stock is rising or falling in short-term value. The BVS shares have gain 11.47% over the last week, with a monthly amount glided 3.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bioventus Inc [NASDAQ: BVS] stock has seen the most recent analyst activity on July 07, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $12. Previously, JP Morgan upgraded its rating to Neutral on December 17, 2024, and elevated its price target to $13. On December 07, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $7 on the stock. Craig Hallum upgraded its rating to a Buy and increased its price target to $6 on August 09, 2023. Craig Hallum downgraded its rating to a Hold. JP Morgan downgraded its rating to Underweight for this stock on November 09, 2022. In a note dated November 09, 2022, Canaccord Genuity downgraded an Hold rating on this stock and revised its target price from $18 to $6.
For the past year, the stock price of Bioventus Inc fluctuated between $5.81 and $14.38. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Bioventus Inc [NASDAQ: BVS] shares were valued at $7.29 at the most recent close of the market. An investor can expect a potential return of 105.76% based on the average BVS price forecast.
Analyzing the BVS fundamentals
According to Bioventus Inc [NASDAQ:BVS], the company’s sales were 567.70M for trailing twelve months, which represents an -4.31% plunge. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.0%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Bioventus Inc [NASDAQ:BVS] has a current ratio of 1.43. On the other hand, the Quick Ratio is 0.89, and the Cash Ratio is 0.18. Considering the valuation of this stock, the price to sales ratio is 1.05, the price to book ratio is 3.26.
Transactions by insiders
Recent insider trading involved Singleton Mark Leonard, SVP & CFO, that happened on Apr 11 ’25 when 3875.0 shares were sold. SVP & General Counsel, D’Adamio Anthony completed a deal on Apr 11 ’25 to sell 2958.0 shares. Meanwhile, SVP & Chief Compliance Officer CHURCH KATRINA J sold 1283.0 shares on Apr 11 ’25.
